Pharmacovigilance legislation that came into force in the EU in 2012 was the biggest change to the regulation of human medicines in the European Union (EU) since 1995. (EMA).
It has implications for regulators, HCPs, pharmaceutical companies and patients. However, has the value of the new legislation been understood by all parties? Or is it seen as another level of bureaucratic burden to add to an already full workload?
That is a question we’ve been tackling recently as we work on the piece for ABPI to clarify how all stakeholders can play a role in pharmacovigilance. Here we look at some of the benefits and the value the legislation can add from a couple of different viewpoints.
The result is now available online on The Royal Pharmaceutical Society website, you can see the full poster here.